Corning (GLW) Stock Surges as UBS Lifts Price Target to $160 on AI-Driven Fiber Optic Demand 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Renault Acquires Full Control of Flexis Electric Van Venture from Volvo AB and CMA-CGM 
Samsung Stock Hits Record High on Nvidia HBM4 Supply Deal, Boosting AI Chip Rally 
Microsoft Gaming Leadership Shake-Up: Phil Spencer Retires, Asha Sharma Named New Xbox CEO 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
OpenAI Targets $600B Compute Spend as IPO Valuation Could Reach $1 Trillion 
Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Novo Nordisk shares plunged more than 10% in mid-morning trading in Copenhagen on Monday after the pharmaceutical giant announced that its experimental obesity drug, CagriSema, failed to meet a primary endpoint in a closely watched clinical trial. The update intensifies competition in the rapidly expanding weight loss drug market, where Novo Nordisk faces mounting pressure from rival Eli Lilly.
The 84-week open-label head-to-head study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly’s blockbuster obesity treatment, Tirzepatide, in reducing body weight. According to Novo Nordisk, patients treated with CagriSema achieved an average weight loss of 23%, while those receiving Tirzepatide recorded a superior 25.5% reduction. As a result, the trial did not meet its primary objective of proving that CagriSema was not lagging behind Tirzepatide in weight loss efficacy.
The disappointing trial results sent Novo Nordisk stock sharply lower, adding to a challenging year for the Danish drugmaker. In 2025, Novo shares have fallen by 49%, reflecting investor concerns over intensifying competition and shifting dynamics in the obesity treatment sector. The company previously secured a dominant position with its blockbuster drugs Wegovy and Ozempic, both of which fueled significant growth amid surging global demand for weight management medications.
However, competition has grown fiercer, particularly from Eli Lilly, whose Tirzepatide has gained significant traction. Additionally, telehealth providers offering lower-cost compounded alternatives have further pressured pricing and market share.
Despite the setback, Novo Nordisk confirmed that CagriSema was submitted to the U.S. Food and Drug Administration (FDA) for approval in December, with a regulatory decision expected by late 2026. The company recently announced board-level changes, including the appointment of industry veterans and Lars Rebien Sorensen as chairman, signaling a strategic push to strengthen leadership and respond more aggressively to U.S. market challenges.
Investors will now closely monitor regulatory developments and Novo Nordisk’s strategy to defend its position in the booming obesity drug market.
